ArticleEBioMedicine2016
Multiplexed Serum Biomarkers for the Detection of Lung Cancer.
Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Machine learning and discriminant analysis model for predicting benign and malignant pulmonary nodules.BMC medical informatics and decision making · 2025Article
- Microfluidic Device for Patient-Centric Multiplexed Assays with Readout in Centralized Laboratories.Analytical chemistry · 2023Article
- Molecular Origin of Blood-Based Infrared Spectroscopic Fingerprints*.Angewandte Chemie (International ed. in English) · 2021Article
- Malignancy Prediction Capacity and Possible Prediction Model of Circulating Tumor Cells for Suspicious Pulmonary Lesions.Journal of personalized medicine · 2021Article
- Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients.JAMA oncology · 2020Article
- Emerging non-invasive detection methodologies for lung cancer.Oncology letters · 2020Review
- MicroRNA BiomarkerInternational journal of genomics · 2020Article
- Risk prediction models for lung cancer: Perspectives and dissemination.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- Blood based biomarkers beyond genomics for lung cancer screening.Translational lung cancer research · 2018Review
- Measurement of Lung Cancer Tumor Markers in a Glass Wool Company Workers Exposed to Respirable Synthetic Vitreous Fiber and Dust.The international journal of occupational and environmental medicine · 2018Article
- Using the New CellCollector to Capture Circulating Tumor Cells from Blood in Different Groups of Pulmonary Disease: A Cohort Study.Scientific reports · 2017Article
- Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer.Oncotarget · 2017Article
- Identification of potential serum biomarkers for breast cancer using a functional proteomics technology.Biomarker research · 2017Article
- Four Is Better Than 1-Strength in Numbers!EBioMedicine · 2016Article
- A Quest for New Cancer Diagnosis, Prognosis and Prediction Biomarkers and Their Use in Biosensors Development.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, there is no available biomarker for lung cancer diagnosis. Here we recruited 844 lung cancer patients and 620 healthy participants from six hospitals. A total of four serum proteins was identified and subsequently assessed in the training and validation cohorts. The concentrations of four serum proteins were found to be significantly higher in lung cancer patients compared with healthy participants. The area under the curve (AUC) for the 4-biomarker were 0.86 in the training cohort, and 0.87 in the validation cohort. The classification improved to a corrected AUC of 0.90 and 0.89 respectively following addition of sex, age and smoking status. Similar results were observed for early-stage lung cancer. Remarkably, in a blinded test with a suspicious pulmonary nodule, the adjusted prediction model correctly discriminated the patients with 86.96% sensitivity and 98.25% specificity. These results demonstrated the 4-biomarker panel improved lung cancer prediction beyond that of known risk factors. Moreover, the biomarkers were valuable in differentiating benign nodules which will remain indolent from those that are likely to progress and therefore might serve as an adjuvant diagnosis tool for LDCT scanning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.